Immunopotentiators In Modern Vaccines by Virgil SchijnsImmunopotentiators In Modern Vaccines by Virgil Schijns

Immunopotentiators In Modern Vaccines

byVirgil SchijnsEditorDerek O'hagan

Hardcover | November 14, 2016

not yet rated|write a review

Pricing and Purchase Info

$204.11 online 
$224.50 list price save 9%
Earn 1021 plum® points

In stock online

Ships free on orders over $25

Not available in stores


Immunopotentiators in Modern Vaccines, Second Edition,provides in-depth insights and overviews of the most successful adjuvants, those that have been included in licensed products, also covering the most promising technologies that have emerged in recent years. In contrast to existing books on the subject, the chapters here provide summaries of key data on the mechanisms of action of the individual vaccine adjuvants.

In addition, the book covers key aspects of how the technologies might be further developed and what might be their limitations, while also giving an overview of what made the most advanced adjuvant technologies successful.

  • Provides contributions from leading international authorities in the field
  • Features immunopotentiators classified by function, with well-illustrated, informative figures presenting the interaction between the immunopotentiators and the host immune system
  • Lists advantages and potential hurdles for achieving a practical application for each specific immunopotentiator
  • Offers US FDA perspectives which highlight how future adjuvants will be approved for new generation vaccines

About The Author

Dr. Virgil E.J.C. Schijns is special guest Professor in Cell Biology & Immunology group, Wageningen University, 6708 WD Wageningen, The Netherlands. Dr. Schijns received his Ph.D. degree at Utrecht University in 1990. Recent professional appointments are Chief Scientific Officer at ERC in Belgium and The Netherlands, (2011 to present);...
Immunopotentiators in Modern Vaccines
Immunopotentiators in Modern Vaccines

by Virgil Schijns


Available for download

Not available in stores

Details & Specs

Title:Immunopotentiators In Modern VaccinesFormat:HardcoverDimensions:508 pages, 9.41 × 7.24 × 0.98 inPublished:November 14, 2016Publisher:Academic PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:012804019X

ISBN - 13:9780128040195

Look for similar items by category:

Customer Reviews of Immunopotentiators In Modern Vaccines


Extra Content

Table of Contents

Chapter 1. Vaccine Adjuvants' Mode of Action: Unraveling the Immunologist's Dirty Little Secret

Chapter 2. The Role of Inflammasomes in Adjuvant-Driven Humoral and Cellular Immune Responses

Chapter 3. Dendritic Cells as Targets of Vaccines and Adjuvants

Chapter 4. Host-Derived Cytokines and Chemokines as Vaccine Adjuvants

Chapter 5. Discovery of Immune Potentiators as Vaccine Adjuvants

Chapter 6. Current Status of Toll-Like Receptor 4 Ligand Vaccine Adjuvants

Chapter 7. Flagellins as Adjuvants of Vaccines

Chapter 8. Toll-Like Receptor 7 and 8 Agonists for Vaccine Adjuvant Use

Chapter 9. CpG Oligodeoxynucleotides as Adjuvants for Clinical Use

Chapter 10. Advax Adjuvant: A Potent and Safe Immunopotentiator Composed of Delta Inulin

Chapter 11. Natural Vaccine Adjuvants and Immunopotentiators Derived From Plants, Fungi, Marine Organisms, and Insects

Chapter 12. Polymeric Particles as Vaccine Delivery Systems

Chapter 13. MF59: A Safe and Potent Adjuvant for Human Use

Chapter 14. The Development of the Adjuvant System AS01: A Combination of Two Immunostimulants MPL and QS-21 in Liposomes

Chapter 15. Development and Evaluation of AS04, a Novel and Improved Adjuvant System Containing 3-O-Desacyl-42 - Monophosphoryl Lipid A and Aluminum Salt

Chapter 16. ISCOMATRIX Adjuvant in the Development of Prophylactic and Therapeutic Vaccines

Chapter 17. Development and Evaluation of CAF01

Chapter 18. Mineral Adjuvants

Chapter 19. Toxin-Based Mucosal Adjuvants

Chapter 20. Adjuvants for Skin Vaccination

Chapter 21. Vaccination to Treat Noninfectious Diseases: Surveying the Opportunities

Chapter 22. A Framework for Evaluating Nonclinical Safety of Novel Adjuvants and Adjuvanted Preventive Vaccines